Economics of Artificial Intelligence in Healthcare: Diagnosis vs. Treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khanna Narendra N, Maindarkar Mahesh A, Viswanathan Vijay, Fernandes Jose Fernandes E, Paul Sudip, Bhagawati Mrinalini, Ahluwalia Puneet, Ruzsa Zoltan, Sharma Aditya, Kolluri Raghu, Singh Inder M, Laird John R, Fatemi Mostafa, Alizad Azra, Saba Luca, Agarwal Vikas, Sharma Aman, Teji Jagjit S, Al-Maini Mustafa, Rathore Vijay, Naidu Subbaram, Liblik Kiera, Johri Amer M, Turk Monika, Mohanty Lopamudra, Sobel David W, Miner Martin, Viskovic Klaudija, Tsoulfas George, Protogerou Athanasios D, Kitas George D, Fouda Mostafa M, Chaturvedi Seemant, Kalra Mannudeep K, Suri Jasjit S
Аннотация
Motivation: The price of medical treatment continues to rise due to (i) an increasing population; (ii) an aging human growth; (iii) disease prevalence; (iv) a rise in the frequency of patients that utilize health care services; and (v) increase in the price. Objective: Artificial Intelligence (AI) is already well-known for its superiority in various healthcare applications, including the segmentation of lesions in images, speech recognition, smartphone personal assistants, navigation, ride-sharing apps, and many more. Our study is based on two hypotheses: (i) AI offers more economic solutions compared to conventional methods; (ii) AI treatment offers stronger economics compared to AI diagnosis. This novel study aims to evaluate AI technology in the context of healthcare costs, namely in the areas of diagnosis and treatment, and then compare it to the traditional or non-AI-based approaches. Methodology: PRISMA was used to select the best 200 studies for AI in healthcare with a primary focus on cost reduction, especially towards diagnosis and treatment. We defined the diagnosis and treatment architectures, investigated their characteristics, and categorized the roles that AI plays in the diagnostic and therapeutic paradigms. We experimented with various combinations of different assumptions by integrating AI and then comparing it against conventional costs. Lastly, we dwell on three powerful future concepts of AI, namely, pruning, bias, explainability, and regulatory approvals of AI systems. Conclusions: The model shows tremendous cost savings using AI tools in diagnosis and treatment. The economics of AI can be improved by incorporating pruning, reduction in AI bias, explainability, and regulatory approvals.